Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Strong decline of tuberculosis in the Netherlands The number of tuberculosis (TB) patients in the Netherlands decreased considerably in 2017. From 887 patients in 2016 to 787 in 2017.
Sustainability Day at RIVM: Microplastics Today, 10 October 2018, is national Sustainability Day in the Netherlands.
RIVM measures much higher levels of tar, nicotine and carbon monoxide in cigarettes Tar, nicotine and carbon monoxide (TNCO) levels measured in accordance with the Canadian Intense (CI) method are at least twice as high as the levels measured in accordance with the prescribed ISO
Measures to reduce microplastic emissions in the environment Microplastics are plastic particles that are smaller than 5 millimetres; through the use of plastic or rubber products these microplastics can end up in the environment (surface water, soil, and ai
Addictive nicotine and harmful substances also present in heated tobacco Heated tobacco products are newly available on the market. An example of such a product is the heatstick which is heated with an iQOS, a device that looks like an e-cigarette.
RIVM withdraws from tobacco committees The Dutch National Institute for Public Health and the Environment will leave the NEN/CEN/ISO committees for tobacco and e-cigarettes with immediate effect.
Lyme disease cases have quadrupled According to a survey by RIVM , 27,000 people were infected with Lyme disease in 2017. In 2014, the last time RIVM reported on the incidence of tick-borne disease, this number was 25,000.
European critical loads: database, biodiversity and ecosystems at risk Approximately 79 percent of the nature reserves (Natura 2000 areas) in EU countries are estimated to be exposed to an excess of nitrogen deposition in 2020.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.